Open
Do PCSK9 inhibitors improve blood pressure more than other treatments?
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
No claim has formed for this comparison yet. The trials below are registered, but none decides it.
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 5
- With posted results
- 0
- Published papers
- 1
Papers
- Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study.Observational study · 2020
Trials
- Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart DiseaseNCT06421363
- Effect of Evolocumab on Chronic Total Occlusions After Successful Percutaneous Coronary Intervention (EVOLO-CTO)NCT05623995
- Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (EVALUATE-STEMI Trial): a Prospective, Multicenter, Open-label, Adjudicator-blinded, Randomized Clinical TrialNCT05613426
- Effectiveness of Inclisiran for Patients With Coronary Heart Disease in China: a Multicenter, Standard of Care-Controlled Pragmatic Randomized TrialNCT06941792
- EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 TrialNCT03932721